查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1790223

用於早期癌症檢測和監測的液態切片市場規模、佔有率和趨勢分析報告：按生物標記、技術、癌症類型、最終用途、地區和細分市場預測，2025 年至 2033 年

Liquid Biopsy For Early Cancer Detection And Monitoring Market Size, Share & Trends Analysis Report By Biomarker (Circulating Tumor DNA, Circulating Tumor Cells ), By Technology, By Cancer, By End Use, By Region, And Segment Forecasts, 2025 - 2033
出版日期: | 出版商: Grand View Research | 英文 136 Pages | 商品交期: 2-10個工作天內

價格

早期癌症檢測和監測的液態切片市場概述

用於早期癌症檢測和監測的液態切片的全球市場規模預計在 2024 年為 22.3 億美元，預計到 2033 年將達到 62 億美元，2025 年至 2033 年的複合年成長率為 12.14%。該市場專注於旨在早期和準確檢測各種癌症的診斷解決方案，從而能夠及時干預並改善患者的治療效果。

該領域的技術包括分析體液中循環腫瘤DNA (ctDNA)、循環性腫瘤細胞(CTC) 和其他生物標記的平台，為組織活體組織切片提供了侵入性更低的替代方案。這些解決方案正擴大被整合到臨床和研究領域的腫瘤學實踐中，用於早期檢測、治療方法選擇和疾病監測。

液態切片的普及源於癌症發生率的上升，以及對能夠頻繁監測且最大程度減少患者不適的無創技術日益成長的需求。即時檢測腫瘤相關基因變異的能力為腫瘤學家提供了寶貴的資訊，可用於制定治療決策和早期療育策略。

此外，隨著液態切片的應用也日益廣泛，基因組學和分子學見解可為治療決策和縱向護理提供資訊。由新一代定序、數位PCR工作流程和不斷發展的生物資訊工具支援的高靈敏度技術正在幫助檢測低頻突變、微量殘存疾病和新出現的抗藥性訊號。此外，多癌種早期檢測和檢測試劑盒（可分析多種生物標記物，包括DNA、RNA片段、表觀遺傳特徵和細胞外囊泡內容物）的研發，正在將臨床應用從晚期管理擴展到風險評估和人群篩檢。

此外，市場正受到實證項目、監管支援和支付方評估的影響，這些評估著重於與傳統組織學方法相比的臨床價值和成本效益。挑戰依然存在，包括不同平台的檢測性能差異、樣本收集和分析缺乏標準化，以及難以解讀早期疾病中的微弱訊號。某些地區的報銷有限也影響了液體活體組織切片的可及性。正在進行的臨床試驗、真實世界試驗和數據共用工作預計將提供更清晰的指導方針，改進指南，並推動液態切片在早期檢測和持續癌症監測中的更廣泛應用。

用於早期檢測和監測的液態切片的創新強調準確性、可及性和臨床適用性：多組體學整合、人工智慧主導的解釋和先進的測序正在改變檢測和追蹤過程，從而提高對早期疾病的敏感性並提供更加個性化的治療計劃。

多癌種檢測和近患者平台等發展旨在將液態切片擴展到集中式設施之外，從而提高便利性並支持大規模篩檢舉措。微量殘存疾病檢測和持續監測的進展有望促進液態切片在臨床上的更廣泛應用，並加強其在癌症治療中的作用。

目錄

第1章 早期癌症檢測和監測的液態切片市場：調查方法和範圍

2. 早期癌症檢測和監測的液態切片市場：執行摘要

  • 市場概述
  • 生物標記和技術簡介
  • 癌症簡介
  • 最終用途簡介
  • 競爭格局簡介

3.液態切片市場變數、趨勢和早期癌症檢測與監測範圍

  • 市場區隔和範圍
  • 市場體系展望
    • 母市場展望
    • 相關/輔助市場展望
  • 市場動態
  • 市場促進因素分析
    • 非侵入性癌症檢測的需求不斷增加
    • 先進技術的融合
    • 提高臨床採用率和監管核准
  • 市場限制因素分析
    • 液態切片檢測和基礎設施高成本
    • 分析和臨床檢驗的挑戰
  • 波特五力分析
  • PESTLE分析
  • 管道分析

第4章 早期癌症檢測和監測的液態切片市場：生物標記的估計和趨勢分析

  • 早期癌症檢測和監測的液態切片市場：生物標記變異分析
  • 循環腫瘤DNA（CtDNA）
  • 循環性腫瘤細胞（CTC）
  • 外泌體/微泡
  • 循環蛋白

第5章 早期癌症檢測和監測的液態切片市場：技術評估和趨勢分析

  • 早期癌症檢測和監測的液態切片市場：技術變革分析
  • NGS（次世代定序）
  • 基於PCR的檢測（數位PCR、RT-PCR）
  • 微陣列
  • 表觀基因/甲基化分析
  • 其他

第6章。早期癌症檢測和監測的液態切片市場：按癌症類型、估計和趨勢分析

  • 早期癌症檢測和監測的液態切片市場：癌症變異分析
  • 肺癌
  • 乳癌
  • 大腸直腸癌
  • 攝護腺癌
  • 其他

7. 早期癌症檢測和監測液態切片市場（按最終用途、估值和趨勢分析）

  • 早期癌症檢測和監測的液態切片市場：最終用途變異分析
  • 醫院
  • 診斷實驗室
  • 其他

8. 早期癌症檢測和監測液態切片市場：區域業務分析

  • 區域市場概況
  • 北美洲
  • 歐洲
  • 亞太地區
  • 拉丁美洲
  • 中東和非洲

第9章 競爭態勢

  • 公司分類
  • 戰略地圖
    • 推出新的生物標記
    • 夥伴關係
    • 獲得
    • 合作
    • 資金籌措
  • 主要企業市場佔有率分析（2024年）
  • 公司熱圖分析
  • 公司簡介
    • Grail, Inc.
    • Exact Sciences Corporation
    • Anchordx
    • Burning Rock BIoTech Limited
    • Genecast
    • Guardant Health
    • Myriad Genetics, Inc.
    • Elypta Ab
    • Lucence Health Inc.
    • Freenome Holdings, Inc.
    • Oncimmune
Product Code: GVR-4-68040-683-3

Liquid Biopsy For Early Cancer Detection And Monitoring Market Summary

The global liquid biopsy for early cancer detection and monitoring market size was estimated at USD 2.23 billion in 2024 and is projected to reach USD 6.20 billion by 2033, growing at a CAGR of 12.14% from 2025 to 2033. This market focuses on diagnostic solutions designed for the early and accurate detection of various cancers, enabling timely intervention and improved patient outcomes.

Technologies within this segment include platforms for analyzing circulating tumor DNA (ctDNA), circulating tumor cells (CTCs), and other biomarkers from body fluids, offering a less invasive alternative to tissue biopsies. These solutions are increasingly integrated into oncology practices for early detection, therapy selection, and disease monitoring across clinical and research environments.

The adoption of liquid biopsy is supported by rising cancer incidence and the growing need for non-invasive methods that allow frequent monitoring with minimal discomfort to patients. The ability to detect tumor-related genetic changes in real time provides oncologists with valuable information for treatment decisions and early intervention strategies.

Moreover, the adoption of liquid biopsy is increasing as the field moves toward precision oncology, where genomic and molecular insights inform treatment decisions and long-term care. High-sensitivity techniques supported by next-generation sequencing, digital PCR workflows, and advancing bioinformatics tools help detect low-frequency variants, minimal residual disease, and emerging resistance signals. Additionally, efforts in multi-cancer early detection and assay panels that analyze multiple biomarkers such as DNA, RNA fragments, epigenetic signatures, and extracellular vesicle content are broadening clinical applications from late-stage management to risk assessment and population-level screening.

Furthermore, the market is shaped by evidence-generation programs, regulatory support, and payer assessments that focus on clinical value and cost-effectiveness compared to traditional tissue-based methods. Challenges still exist, such as variations in assay performance across platforms, a lack of standardization in sample collection and analysis, and difficulties in interpreting weak signals in early disease stages. Limited reimbursement in some regions also impacts accessibility. Ongoing clinical trials, real-world studies, and data-sharing initiatives are expected to bring clarity, improve guidelines, and promote wider adoption of liquid biopsy for early detection and continuous cancer monitoring.

Innovation in liquid biopsy for early detection and monitoring emphasizes accuracy, accessibility, and clinical applicability. Multi-omics integration, AI-driven interpretation, and advanced sequencing transform detection and tracking processes, enabling higher sensitivity for early-stage disease and more personalized treatment planning.

Developments such as multi-cancer detection assays and near-patient platforms aim to extend liquid biopsies outside centralized facilities, enhancing convenience and supporting large-scale screening initiatives. Progress in minimal residual disease detection and continuous monitoring is expected to drive broader clinical uptake and strengthen liquid biopsy's role in oncology care.

Global Liquid Biopsy For Early Cancer Detection And Monitoring Market Report Segmentation

This report forecasts revenue growth and provides an analysis of the latest trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global liquid biopsy for early cancer detection and monitoring market based on biomarker, technology, cancer, end use, and region:

  • Biomarker Outlook (USD Million; 2021 - 2033)
  • Circulating Tumor DNA (ctDNA)
  • Circulating Tumor Cells (CTCs)
  • Exosomes/Microvesicles
  • Circulating Proteins
  • Technology Outlook (USD Million; 2021 - 2033)
  • NGS (Next-Generation Sequencing)
  • PCR-based assays (Digital PCR, RT-PCR)
  • Microarray
  • Epigenomics / Methylation assays
  • Others
  • Cancer Outlook (USD Million; 2021 - 2033)
  • Lung Cancer
  • Breast Cancer
  • Colorectal Cancer
  • Prostate Cancer
  • Others
  • End Use Outlook (USD Million; 2021 - 2033)
  • Hospitals
  • Diagnostic Laboratories
  • Others
  • Regional Outlook (USD Million, 2021 - 2033)
  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • UK
    • Germany
    • France
    • Italy
    • Spain
    • Denmark
    • Sweden
    • Norway
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • South Korea
    • Thailand
  • Latin America
    • Brazil
    • Argentina
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE
    • Kuwait

Table of Contents

Chapter 1. Liquid Biopsy For Early Cancer Detection And Monitoring Market: Methodology And Scope

  • 1.1. Market Segmentation And Scope
    • 1.1.1. Segment Definitions
      • 1.1.1.1. Biomarker Segment
      • 1.1.1.2. Technology Segment
      • 1.1.1.3. Cancer Segment
      • 1.1.1.4. End Use Segment
  • 1.2. Regional Scope
  • 1.3. Estimates And Forecast Timeline
  • 1.4. Objectives
    • 1.4.1. Objective - 1
    • 1.4.2. Objective - 2
    • 1.4.3. Objective - 3
  • 1.5. Research Methodology
  • 1.6. Information Procurement
    • 1.6.1. Purchased Database
    • 1.6.2. Gvr's Internal Database
    • 1.6.3. Secondary Sources
    • 1.6.4. Primary Research
  • 1.7. Information Or Data Analysis
    • 1.7.1. Data Analysis Models
  • 1.8. Market Formulation & Validation
  • 1.9. Model Details
    • 1.9.1. Commodity Flow Analysis
  • 1.10. List Of Secondary Sources
  • 1.11. List Of Abbreviations

Chapter 2. Liquid Biopsy For Early Cancer Detection And Monitoring Market: Executive Summary

  • 2.1. Market Snapshot
  • 2.2. Biomarker And Technology Snapshot
  • 2.3. Cancer Snapshot
  • 2.4. End Use Snapshot
  • 2.5. Competitive Landscape Snapshot

Chapter 3. Liquid Biopsy For Early Cancer Detection And Monitoring Market Variables, Trends, & Scope

  • 3.1. Market Segmentation And Scope
  • 3.2. Market Lineage Outlook
    • 3.2.1. Parent Market Outlook
    • 3.2.2. Related/Ancillary Market Outlook
  • 3.3. Market Dynamics
  • 3.4. Market Drivers Analysis
    • 3.4.1. Growing Demand For Non-Invasive Cancer Screening
    • 3.4.2. Integration Of Advanced Technologies
    • 3.4.3. Increasing Clinical Adoption And Regulatory Approvals
  • 3.5. Market Restraint Analysis
    • 3.5.1. High Cost Of Liquid Biopsy Tests And Infrastructure
    • 3.5.2. Analytical And Clinical Validation Challenges
  • 3.6. Porter's Five Forces Analysis
  • 3.7. Pestle Analysis
  • 3.8. Pipeline Analysis

Chapter 4. Liquid Biopsy For Early Cancer Detection And Monitoring Market: Biomarker Estimates & Trend Analysis

  • 4.1. Liquid Biopsy For Early Cancer Detection And Monitoring Market: Biomarker Movement Analysis
  • 4.2. Circulating Tumor Dna (Ctdna)
    • 4.2.1. Market Estimates And Forecasts, 2021 - 2033 (USD Million)
  • 4.3. Circulating Tumor Cells (Ctcs)
    • 4.3.1. Market Estimates And Forecasts, 2021 - 2033 (USD Million)
  • 4.4. Exosomes/Microvesicles
    • 4.4.1. Market Estimates And Forecasts, 2021 - 2033 (USD Million)
  • 4.5. Circulating Proteins
    • 4.5.1. Market Estimates And Forecasts, 2021 - 2033 (USD Million)

Chapter 5. Liquid Biopsy For Early Cancer Detection And Monitoring Market: Technology Estimates & Trend Analysis

  • 5.1. Liquid Biopsy For Early Cancer Detection And Monitoring Market: Technology Movement Analysis
  • 5.2. Ngs (Next-Generation Sequencing)
    • 5.2.1. Market Revenue Estimates And Forecasts, 2021 - 2033 (USD Million)
  • 5.3. Pcr-Based Assays (Digital Pcr, Rt-Pcr)
    • 5.3.1. Market Revenue Estimates And Forecasts, 2021 - 2033 (USD Million)
  • 5.4. Microarray
    • 5.4.1. Market Revenue Estimates And Forecasts, 2021 - 2033 (USD Million)
  • 5.5. Epigenomics / Methylation Assays
    • 5.5.1. Market Revenue Estimates And Forecasts, 2021 - 2033 (USD Million)
  • 5.6. Others
    • 5.6.1. Market Revenue Estimates And Forecasts, 2021 - 2033 (USD Million)

Chapter 6. Liquid Biopsy For Early Cancer Detection And Monitoring Market: Cancer Estimates & Trend Analysis

  • 6.1. Liquid Biopsy For Early Cancer Detection And Monitoring Market: Cancer Movement Analysis
  • 6.2. Lung Cancer
    • 6.2.1. Market Revenue Estimates And Forecasts, 2021 - 2033 (USD Million)
  • 6.3. Breast Cancer
    • 6.3.1. Market Revenue Estimates And Forecasts, 2021 - 2033 (USD Million)
  • 6.4. Colorectal Cancer
    • 6.4.1. Market Revenue Estimates And Forecasts, 2021 - 2033 (USD Million)
  • 6.5. Prostate Cancer
    • 6.5.1. Market Revenue Estimates And Forecasts, 2021 - 2033 (USD Million)
  • 6.6. Others
    • 6.6.1. Market Revenue Estimates And Forecasts, 2021 - 2033 (USD Million)

Chapter 7. Liquid Biopsy For Early Cancer Detection And Monitoring Market: End Use Estimates & Trend Analysis

  • 7.1. Liquid Biopsy For Early Cancer Detection And Monitoring Market: End Use Movement Analysis
  • 7.2. Hospitals
    • 7.2.1. Market Revenue Estimates And Forecasts, 2021 - 2033 (USD Million)
  • 7.3. Diagnostic Laboratories
    • 7.3.1. Market Revenue Estimates And Forecasts, 2021 - 2033 (USD Million)
  • 7.4. Others
    • 7.4.1. Market Revenue Estimates And Forecasts, 2021 - 2033 (USD Million)

Chapter 8. Liquid Biopsy For Early Cancer Detection And Monitoring Market: Regional Business Analysis

  • 8.1. Regional Market Snapshot
  • 8.2. North America
    • 8.2.1. North America Liquid Biopsy For Early Cancer Detection And Monitoring Market Estimates And Forecast, 2021 - 2033 (USD Million)
    • 8.2.2. U.S.
      • 8.2.2.1. U.S. Liquid Biopsy For Early Cancer Detection And Monitoring Market, 2021 - 2033 (USD Million)
      • 8.2.2.2. Key Country Dynamics
      • 8.2.2.3. Regulatory Framework
      • 8.2.2.4. Reimbursement Scenario
      • 8.2.2.5. Competitive Scenario
    • 8.2.3. Canada
      • 8.2.3.1. Canada Liquid Biopsy For Early Cancer Detection And Monitoring Market, 2021 - 2033 (USD Million)
      • 8.2.3.2. Key Country Dynamics
      • 8.2.3.3. Regulatory Framework
      • 8.2.3.4. Reimbursement Scenario
      • 8.2.3.5. Competitive Scenario
    • 8.2.4. Mexico
      • 8.2.4.1. Mexico Liquid Biopsy For Early Cancer Detection And Monitoring Market, 2021 - 2033 (USD Million)
      • 8.2.4.2. Key Country Dynamics
      • 8.2.4.3. Regulatory Framework
      • 8.2.4.4. Reimbursement Scenario
      • 8.2.4.5. Competitive Scenario
  • 8.3. Europe
    • 8.3.1. Europe Liquid Biopsy For Early Cancer Detection And Monitoring Market, 2021 - 2033 (USD Million)
    • 8.3.2. UK
      • 8.3.2.1. UK Liquid Biopsy For Early Cancer Detection And Monitoring Market, 2021 - 2033 (USD Million)
      • 8.3.2.2. Key Country Dynamics
      • 8.3.2.3. Regulatory Framework
      • 8.3.2.4. Reimbursement Scenario
      • 8.3.2.5. Competitive Scenario
    • 8.3.3. Germany
      • 8.3.3.1. Germany Liquid Biopsy For Early Cancer Detection And Monitoring Market, 2021 - 2033 (USD Million)
      • 8.3.3.2. Key Country Dynamics
      • 8.3.3.3. Regulatory Framework
      • 8.3.3.4. Reimbursement Scenario
      • 8.3.3.5. Competitive Scenario
    • 8.3.4. Spain
      • 8.3.4.1. Spain Liquid Biopsy For Early Cancer Detection And Monitoring Market, 2021 - 2033 (USD Million)
      • 8.3.4.2. Key Country Dynamics
      • 8.3.4.3. Regulatory Framework
      • 8.3.4.4. Reimbursement Scenario
      • 8.3.4.5. Competitive Scenario
    • 8.3.5. France
      • 8.3.5.1. France Liquid Biopsy For Early Cancer Detection And Monitoring Market, 2021 - 2033 (USD Million)
      • 8.3.5.2. Key Country Dynamics
      • 8.3.5.3. Regulatory Framework
      • 8.3.5.4. Reimbursement Scenario
      • 8.3.5.5. Competitive Scenario
    • 8.3.6. Italy
      • 8.3.6.1. Italy Liquid Biopsy For Early Cancer Detection And Monitoring Market, 2021 - 2033 (USD Million)
      • 8.3.6.2. Key Country Dynamics
      • 8.3.6.3. Regulatory Framework
      • 8.3.6.4. Reimbursement Scenario
      • 8.3.6.5. Competitive Scenario
    • 8.3.7. Denmark
      • 8.3.7.1. Denmark Liquid Biopsy For Early Cancer Detection And Monitoring Market, 2021 - 2033 (USD Million)
      • 8.3.7.2. Key Country Dynamics
      • 8.3.7.3. Regulatory Framework
      • 8.3.7.4. Reimbursement Scenario
      • 8.3.7.5. Competitive Scenario
    • 8.3.8. Sweden
      • 8.3.8.1. Sweden Liquid Biopsy For Early Cancer Detection And Monitoring Market, 2021 - 2033 (USD Million)
      • 8.3.8.2. Key Country Dynamics
      • 8.3.8.3. Regulatory Framework
      • 8.3.8.4. Reimbursement Scenario
      • 8.3.8.5. Competitive Scenario
    • 8.3.9. Norway
      • 8.3.9.1. Norway Liquid Biopsy For Early Cancer Detection And Monitoring Market, 2021 - 2033 (USD Million)
      • 8.3.9.2. Key Country Dynamics
      • 8.3.9.3. Regulatory Framework
      • 8.3.9.4. Reimbursement Scenario
      • 8.3.9.5. Competitive Scenario
  • 8.4. Asia Pacific
    • 8.4.1. Asia-Pacific Liquid Biopsy For Early Cancer Detection And Monitoring Market, 2021 - 2033 (USD Million)
    • 8.4.2. Japan
      • 8.4.2.1. Japan Liquid Biopsy For Early Cancer Detection And Monitoring Market, 2021 - 2033 (USD Million)
      • 8.4.2.2. Key Country Dynamics
      • 8.4.2.3. Regulatory Framework
      • 8.4.2.4. Reimbursement Scenario
      • 8.4.2.5. Competitive Scenario
    • 8.4.3. China
      • 8.4.3.1. China Liquid Biopsy For Early Cancer Detection And Monitoring Market, 2021 - 2033 (USD Million)
      • 8.4.3.2. Key Country Dynamics
      • 8.4.3.3. Regulatory Framework
      • 8.4.3.4. Reimbursement Scenario
      • 8.4.3.5. Competitive Scenario
    • 8.4.4. India
      • 8.4.4.1. India Liquid Biopsy For Early Cancer Detection And Monitoring Market, 2021 - 2033 (USD Million)
      • 8.4.4.2. Key Country Dynamics
      • 8.4.4.3. Regulatory Framework
      • 8.4.4.4. Reimbursement Scenario
      • 8.4.4.5. Competitive Scenario
    • 8.4.5. South Korea
      • 8.4.5.1. South Korea Liquid Biopsy For Early Cancer Detection And Monitoring Market, 2021 - 2033 (USD Million)
      • 8.4.5.2. Key Country Dynamics
      • 8.4.5.3. Regulatory Framework
      • 8.4.5.4. Reimbursement Scenario
      • 8.4.5.5. Competitive Scenario
    • 8.4.6. Thailand
      • 8.4.6.1. Thailand Liquid Biopsy For Early Cancer Detection And Monitoring Market, 2021 - 2033 (USD Million)
      • 8.4.6.2. Key Country Dynamics
      • 8.4.6.3. Regulatory Framework
      • 8.4.6.4. Reimbursement Scenario
      • 8.4.6.5. Competitive Scenario
    • 8.4.7. Australia
      • 8.4.7.1. Australia Liquid Biopsy For Early Cancer Detection And Monitoring Market, 2021 - 2033 (USD Million)
      • 8.4.7.2. Key Country Dynamics
      • 8.4.7.3. Regulatory Framework
      • 8.4.7.4. Reimbursement Scenario
      • 8.4.7.5. Competitive Scenario
  • 8.5. Latin America
    • 8.5.1. Latin America Liquid Biopsy For Early Cancer Detection And Monitoring Market, 2021 - 2033 (USD Million)
    • 8.5.2. Brazil
      • 8.5.2.1. Brazil Liquid Biopsy For Early Cancer Detection And Monitoring Market, 2021 - 2033 (USD Million)
      • 8.5.2.2. Key Country Dynamics
      • 8.5.2.3. Regulatory Framework
      • 8.5.2.4. Reimbursement Scenario
      • 8.5.2.5. Competitive Scenario
    • 8.5.3. Argentina
      • 8.5.3.1. Argentina Liquid Biopsy For Early Cancer Detection And Monitoring Market, 2021 - 2033 (USD Million)
      • 8.5.3.2. Key Country Dynamics
      • 8.5.3.3. Regulatory Framework
      • 8.5.3.4. Reimbursement Scenario
      • 8.5.3.5. Competitive Scenario
  • 8.6. MEA
    • 8.6.1. MEA Liquid Biopsy For Early Cancer Detection And Monitoring Market, 2021 - 2033 (USD Million)
    • 8.6.2. South Africa
      • 8.6.2.1. South Africa Liquid Biopsy For Early Cancer Detection And Monitoring Market, 2021 - 2033 (USD Million)
      • 8.6.2.2. Key Country Dynamics
      • 8.6.2.3. Regulatory Framework
      • 8.6.2.4. Reimbursement Scenario
      • 8.6.2.5. Competitive Scenario
    • 8.6.3. Saudi Arabia
      • 8.6.3.1. Saudi Arabia Liquid Biopsy For Early Cancer Detection And Monitoring Market, 2021 - 2033 (USD Million)
      • 8.6.3.2. Key Country Dynamics
      • 8.6.3.3. Regulatory Framework
      • 8.6.3.4. Reimbursement Scenario
      • 8.6.3.5. Competitive Scenario
    • 8.6.4. UAE
      • 8.6.4.1. UAE Liquid Biopsy For Early Cancer Detection And Monitoring Market, 2021 - 2033 (USD Million)
      • 8.6.4.2. Key Country Dynamics
      • 8.6.4.3. Regulatory Framework
      • 8.6.4.4. Reimbursement Scenario
      • 8.6.4.5. Competitive Scenario
    • 8.6.5. Kuwait
      • 8.6.5.1. Kuwait Liquid Biopsy For Early Cancer Detection And Monitoring Market, 2021 - 2033 (USD Million)
      • 8.6.5.2. Key Country Dynamics
      • 8.6.5.3. Regulatory Framework
      • 8.6.5.4. Reimbursement Scenario
      • 8.6.5.5. Competitive Scenario

Chapter 9. Competitive Landscape

  • 9.1. Company Categorization
  • 9.2. Strategy Mapping
    • 9.2.1. New Biomarker Launch
    • 9.2.2. Partnerships
    • 9.2.3. Acquisition
    • 9.2.4. Collaboration
    • 9.2.5. Funding
  • 9.3. Key Company Market Share Analysis, 2024
  • 9.4. Company Heat Map Analysis
  • 9.5. Company Profiles
    • 9.5.1. Grail, Inc.
      • 9.5.1.1. Company Overview
      • 9.5.1.2. Financial Performance
      • 9.5.1.3. Biomarker Benchmarking
      • 9.5.1.4. Strategic Initiatives
    • 9.5.2. Exact Sciences Corporation
      • 9.5.2.1. Company Overview
      • 9.5.2.2. Financial Performance
      • 9.5.2.3. Biomarker Benchmarking
      • 9.5.2.4. Strategic Initiatives
    • 9.5.3. Anchordx
      • 9.5.3.1. Company Overview
      • 9.5.3.2. Financial Performance
      • 9.5.3.3. Biomarker Benchmarking
      • 9.5.3.4. Strategic Initiatives
    • 9.5.4. Burning Rock Biotech Limited
      • 9.5.4.1. Company Overview
      • 9.5.4.2. Financial Performance
      • 9.5.4.3. Biomarker Benchmarking
      • 9.5.4.4. Strategic Initiatives
    • 9.5.5. Genecast
      • 9.5.5.1. Company Overview
      • 9.5.5.2. Financial Performance
      • 9.5.5.3. Biomarker Benchmarking
      • 9.5.5.4. Strategic Initiatives
    • 9.5.6. Guardant Health
      • 9.5.6.1. Company Overview
      • 9.5.6.2. Financial Performance
      • 9.5.6.3. Biomarker Benchmarking
      • 9.5.6.4. Strategic Initiatives
    • 9.5.7. Myriad Genetics, Inc.
      • 9.5.7.1. Company Overview
      • 9.5.7.2. Financial Performance
      • 9.5.7.3. Biomarker Benchmarking
      • 9.5.7.4. Strategic Initiatives
    • 9.5.8. Elypta Ab
      • 9.5.8.1. Company Overview
      • 9.5.8.2. Financial Performance
      • 9.5.8.3. Biomarker Benchmarking
      • 9.5.8.4. Strategic Initiatives
    • 9.5.9. Lucence Health Inc.
      • 9.5.9.1. Company Overview
      • 9.5.9.2. Financial Performance
      • 9.5.9.3. Biomarker Benchmarking
      • 9.5.9.4. Strategic Initiatives
    • 9.5.10. Freenome Holdings, Inc.
      • 9.5.10.1. Company Overview
      • 9.5.10.2. Financial Performance
      • 9.5.10.3. Biomarker Benchmarking
      • 9.5.10.4. Strategic Initiatives
    • 9.5.11. Oncimmune
      • 9.5.11.1. Company Overview
      • 9.5.11.2. Financial Performance
      • 9.5.11.3. Biomarker Benchmarking
      • 9.5.11.4. Strategic Initiatives

List of Tables

  • Table 1 List of Secondary Sources
  • Table 2 List of Abbreviation
  • Table 3 Global liquid biopsy for early cancer detection and monitoring market, by region, 2021 - 2033 (USD Million)
  • Table 4 Global liquid biopsy for early cancer detection and monitoring market, By Cancer, 2021 - 2033 (USD Million)
  • Table 5 Global liquid biopsy for early cancer detection and monitoring market, By Biomarker, 2021 - 2033 (USD Million)
  • Table 6 Global liquid biopsy for early cancer detection and monitoring market, By Technology, 2021 - 2033 (USD Million)
  • Table 7 Global liquid biopsy for early cancer detection and monitoring market, By End Use, 2021 - 2033 (USD Million)
  • Table 8 North America Liquid Biopsy for Early Cancer Detection and Monitoring Market, By Country, 2021 - 2033 (USD Million)
  • Table 9 North America Liquid Biopsy for Early Cancer Detection and Monitoring Market, By Cancer, 2021 - 2033 (USD Million)
  • Table 10 North America Liquid Biopsy for Early Cancer Detection and Monitoring Market, By Biomarker, 2021 - 2033 (USD Million)
  • Table 11 North America Liquid Biopsy for Early Cancer Detection and Monitoring Market, By Technology, 2021 - 2033 (USD Million)
  • Table 12 North America Liquid Biopsy for Early Cancer Detection and Monitoring Market, By End Use, 2021 - 2033 (USD Million)
  • Table 13 U.S. Liquid Biopsy for Early Cancer Detection and Monitoring Market, by Cancer, 2021 - 2033 (USD Million)
  • Table 14 U.S. Liquid Biopsy for Early Cancer Detection and Monitoring Market, By Biomarker, 2021 - 2033 (USD Million)
  • Table 15 U.S. Liquid Biopsy for Early Cancer Detection and Monitoring Market, By Technology, 2021 - 2033 (USD Million)
  • Table 16 U.S. Liquid Biopsy for Early Cancer Detection and Monitoring Market, By End Use, 2021 - 2033 (USD Million)
  • Table 17 Canada Liquid Biopsy for Early Cancer Detection and Monitoring Market, By Cancer, 2021 - 2033 (USD Million)
  • Table 18 Canada Liquid Biopsy for Early Cancer Detection and Monitoring Market, by Biomarker, 2021 - 2033 (USD Million)
  • Table 19 Canada Liquid Biopsy for Early Cancer Detection and Monitoring Market, by Technology, 2021 - 2033 (USD Million)
  • Table 20 Canada Liquid Biopsy for Early Cancer Detection and Monitoring Market, By End Use, 2021 - 2033 (USD Million)
  • Table 21 Mexico liquid biopsy for early cancer detection and monitoring market, by Cancer, 2021 - 2033 (USD Million)
  • Table 22 Mexico Liquid Biopsy for Early Cancer Detection and Monitoring Market, By Biomarker, 2021 - 2033 (USD Million)
  • Table 23 Mexico Liquid Biopsy for Early Cancer Detection and Monitoring Market, By Technology, 2021 - 2033 (USD Million)
  • Table 24 Mexico Liquid Biopsy for Early Cancer Detection and Monitoring Market, By End Use, 2021 - 2033 (USD Million)
  • Table 25 Europe liquid biopsy for early cancer detection and monitoring market, by country, 2021 - 2033 (USD Million)
  • Table 26 Europe liquid biopsy for early cancer detection and monitoring market, by Cancer, 2021 - 2033 (USD Million)
  • Table 27 Europe Liquid Biopsy for Early Cancer Detection and Monitoring Market, By Biomarker, 2021 - 2033 (USD Million)
  • Table 28 Europe Liquid Biopsy for Early Cancer Detection and Monitoring Market, By Technology, 2021 - 2033 (USD Million)
  • Table 29 Europe Liquid Biopsy for Early Cancer Detection and Monitoring Market, By End Use, 2021 - 2033 (USD Million)
  • Table 30 UK liquid biopsy for early cancer detection and monitoring market, by Cancer, 2021 - 2033 (USD Million)
  • Table 31 UK Liquid Biopsy for Early Cancer Detection and Monitoring Market, By Biomarker, 2021 - 2033 (USD Million)
  • Table 32 UK Liquid Biopsy for Early Cancer Detection and Monitoring Market, By Technology, 2021 - 2033 (USD Million)
  • Table 33 UK Liquid Biopsy for Early Cancer Detection and Monitoring Market, By End Use, 2021 - 2033 (USD Million)
  • Table 34 Germany liquid biopsy for early cancer detection and monitoring market, by Cancer, 2021 - 2033 (USD Million)
  • Table 35 Germany Liquid Biopsy for Early Cancer Detection and Monitoring Market, By Biomarker, 2021 - 2033 (USD Million)
  • Table 36 Germany Liquid Biopsy for Early Cancer Detection and Monitoring Market, By Technology, 2021 - 2033 (USD Million)
  • Table 37 Germany Liquid Biopsy for Early Cancer Detection and Monitoring Market, By End Use, 2021 - 2033 (USD Million)
  • Table 38 France liquid biopsy for early cancer detection and monitoring market, by Cancer, 2021 - 2033 (USD Million)
  • Table 39 France Liquid Biopsy for Early Cancer Detection and Monitoring Market, By Biomarker, 2021 - 2033 (USD Million)
  • Table 40 France Liquid Biopsy for Early Cancer Detection and Monitoring Market, By Technology, 2021 - 2033 (USD Million)
  • Table 41 France Liquid Biopsy for Early Cancer Detection and Monitoring Market, By End Use, 2021 - 2033 (USD Million)
  • Table 42 Italy liquid biopsy for early cancer detection and monitoring market, by Cancer, 2021 - 2033 (USD Million)
  • Table 43 Italy Liquid Biopsy for Early Cancer Detection and Monitoring Market, By Biomarker, 2021 - 2033 (USD Million)
  • Table 44 Italy Liquid Biopsy for Early Cancer Detection and Monitoring Market, By Technology, 2021 - 2033 (USD Million)
  • Table 45 Italy Liquid Biopsy for Early Cancer Detection and Monitoring Market, By End Use, 2021 - 2033 (USD Million)
  • Table 46 Spain liquid biopsy for early cancer detection and monitoring market, by Cancer, 2021 - 2033 (USD Million)
  • Table 47 Spain Liquid Biopsy for Early Cancer Detection and Monitoring Market, By Biomarker, 2021 - 2033 (USD Million)
  • Table 48 Spain Liquid Biopsy for Early Cancer Detection and Monitoring Market, By Technology, 2021 - 2033 (USD Million)
  • Table 49 Spain Liquid Biopsy for Early Cancer Detection and Monitoring Market, By End Use, 2021 - 2033 (USD Million)
  • Table 50 Sweden liquid biopsy for early cancer detection and monitoring market, by Cancer, 2021 - 2033 (USD Million)
  • Table 51 Sweden Liquid Biopsy for Early Cancer Detection and Monitoring Market, By Biomarker, 2021 - 2033 (USD Million)
  • Table 52 Sweden Liquid Biopsy for Early Cancer Detection and Monitoring Market, By Technology, 2021 - 2033 (USD Million)
  • Table 53 Sweden Liquid Biopsy for Early Cancer Detection and Monitoring Market, By End Use, 2021 - 2033 (USD Million)
  • Table 54 Norway liquid biopsy for early cancer detection and monitoring market, by Cancer, 2021 - 2033 (USD Million)
  • Table 55 Norway Liquid Biopsy for Early Cancer Detection and Monitoring Market, By Biomarker, 2021 - 2033 (USD Million)
  • Table 56 Norway Liquid Biopsy for Early Cancer Detection and Monitoring Market, By Technology, 2021 - 2033 (USD Million)
  • Table 57 Norway Liquid Biopsy for Early Cancer Detection and Monitoring Market, By End Use, 2021 - 2033 (USD Million)
  • Table 58 Denmark liquid biopsy for early cancer detection and monitoring market, by Cancer, 2021 - 2033 (USD Million)
  • Table 59 Denmark Liquid Biopsy for Early Cancer Detection and Monitoring Market, By Biomarker, 2021 - 2033 (USD Million)
  • Table 60 Denmark Liquid Biopsy for Early Cancer Detection and Monitoring Market, By Technology, 2021 - 2033 (USD Million)
  • Table 61 Denmark Liquid Biopsy for Early Cancer Detection and Monitoring Market, By End Use, 2021 - 2033 (USD Million)
  • Table 62 Asia Pacific liquid biopsy for early cancer detection and monitoring market, by country, 2021 - 2033 (USD Million)
  • Table 63 Asia Pacific liquid biopsy for early cancer detection and monitoring market, by Cancer, 2021 - 2033 (USD Million)
  • Table 64 Asia Pacific Liquid Biopsy for Early Cancer Detection and Monitoring Market, By Biomarker, 2021 - 2033 (USD Million)
  • Table 65 Asia Pacific Liquid Biopsy for Early Cancer Detection and Monitoring Market, By Technology, 2021 - 2033 (USD Million)
  • Table 66 Asia Pacific Liquid Biopsy for Early Cancer Detection and Monitoring Market, By End Use, 2021 - 2033 (USD Million)
  • Table 67 Japan liquid biopsy for early cancer detection and monitoring market, by Cancer, 2021 - 2033 (USD Million)
  • Table 68 Japan Liquid Biopsy for Early Cancer Detection and Monitoring Market, By Biomarker, 2021 - 2033 (USD Million)
  • Table 69 Japan Liquid Biopsy for Early Cancer Detection and Monitoring Market, By Technology, 2021 - 2033 (USD Million)
  • Table 70 Japan Liquid Biopsy for Early Cancer Detection and Monitoring Market, By End Use, 2021 - 2033 (USD Million)
  • Table 71 China liquid biopsy for early cancer detection and monitoring market, by Cancer, 2021 - 2033 (USD Million)
  • Table 72 China liquid biopsy for early cancer detection and monitoring market, by Biomarker, 2021 - 2033 (USD Million)
  • Table 73 China liquid biopsy for early cancer detection and monitoring market, by Technology, 2021 - 2033 (USD Million)
  • Table 74 China liquid biopsy for early cancer detection and monitoring market, by End Use, 2021 - 2033 (USD Million)
  • Table 75 India liquid biopsy for early cancer detection and monitoring market, by Cancer, 2021 - 2033 (USD Million)
  • Table 76 India liquid biopsy for early cancer detection and monitoring market, by Biomarker, 2021 - 2033 (USD Million)
  • Table 77 India liquid biopsy for early cancer detection and monitoring market, by Technology, 2021 - 2033 (USD Million)
  • Table 78 India liquid biopsy for early cancer detection and monitoring market, by End Use, 2021 - 2033 (USD Million)
  • Table 79 Australia liquid biopsy for early cancer detection and monitoring market, by Cancer, 2021 - 2033 (USD Million)
  • Table 80 Australia liquid biopsy for early cancer detection and monitoring market, by Biomarker, 2021 - 2033 (USD Million)
  • Table 81 Australia liquid biopsy for early cancer detection and monitoring market, by Technology, 2021 - 2033 (USD Million)
  • Table 82 Australia liquid biopsy for early cancer detection and monitoring market, by End Use, 2021 - 2033 (USD Million)
  • Table 83 Thailand liquid biopsy for early cancer detection and monitoring market, by Cancer, 2021 - 2033 (USD Million)
  • Table 84 Thailand liquid biopsy for early cancer detection and monitoring market, by Biomarker, 2021 - 2033 (USD Million)
  • Table 85 Thailand liquid biopsy for early cancer detection and monitoring market, by Technology, 2021 - 2033 (USD Million)
  • Table 86 Thailand liquid biopsy for early cancer detection and monitoring market, by End Use, 2021 - 2033 (USD Million)
  • Table 87 South Korea liquid biopsy for early cancer detection and monitoring market, by Cancer, 2021 - 2033 (USD Million)
  • Table 88 South Korea liquid biopsy for early cancer detection and monitoring market, by Biomarker, 2021 - 2033 (USD Million)
  • Table 89 South Korea liquid biopsy for early cancer detection and monitoring market, by Technology, 2021 - 2033 (USD Million)
  • Table 90 South Korea liquid biopsy for early cancer detection and monitoring market, by End Use, 2021 - 2033 (USD Million)
  • Table 91 Latin America liquid biopsy for early cancer detection and monitoring market, by country, 2021 - 2033 (USD Million)
  • Table 92 Latin America liquid biopsy for early cancer detection and monitoring market, by Cancer, 2021 - 2033 (USD Million)
  • Table 93 Latin America liquid biopsy for early cancer detection and monitoring market, by Biomarker, 2021 - 2033 (USD Million)
  • Table 94 Latin America liquid biopsy for early cancer detection and monitoring market, by Technology, 2021 - 2033 (USD Million)
  • Table 95 Latin America liquid biopsy for early cancer detection and monitoring market, by End Use, 2021 - 2033 (USD Million)
  • Table 96 Brazil liquid biopsy for early cancer detection and monitoring market, by Cancer, 2021 - 2033 (USD Million)
  • Table 97 Brazil liquid biopsy for early cancer detection and monitoring market, by Biomarker, 2021 - 2033 (USD Million)
  • Table 98 Brazil liquid biopsy for early cancer detection and monitoring market, by Technology, 2021 - 2033 (USD Million)
  • Table 99 Brazil liquid biopsy for early cancer detection and monitoring market, by End Use, 2021 - 2033 (USD Million)
  • Table 100 Argentina liquid biopsy for early cancer detection and monitoring market, by Cancer, 2021 - 2033 (USD Million)
  • Table 101 Argentina liquid biopsy for early cancer detection and monitoring market, by Biomarker, 2021 - 2033 (USD Million)
  • Table 102 Argentina liquid biopsy for early cancer detection and monitoring market, by Technology, 2021 - 2033 (USD Million)
  • Table 103 Argentina liquid biopsy for early cancer detection and monitoring market, by End Use, 2021 - 2033 (USD Million)
  • Table 104 MEA liquid biopsy for early cancer detection and monitoring market, by country, 2021 - 2033 (USD Million)
  • Table 105 MEA liquid biopsy for early cancer detection and monitoring market, by Cancer, 2021 - 2033 (USD Million)
  • Table 106 MEA liquid biopsy for early cancer detection and monitoring market, by Biomarker, 2021 - 2033 (USD Million)
  • Table 107 MEA liquid biopsy for early cancer detection and monitoring market, by Technology, 2021 - 2033 (USD Million)
  • Table 108 MEA liquid biopsy for early cancer detection and monitoring market, by End Use, 2021 - 2033 (USD Million)
  • Table 109 South Africa liquid biopsy for early cancer detection and monitoring market, by Cancer, 2021 - 2033 (USD Million)
  • Table 110 South Africa liquid biopsy for early cancer detection and monitoring market, by Biomarker, 2021 - 2033 (USD Million)
  • Table 111 South Africa liquid biopsy for early cancer detection and monitoring market, by Technology, 2021 - 2033 (USD Million)
  • Table 112 South Africa liquid biopsy for early cancer detection and monitoring market, by End Use, 2021 - 2033 (USD Million)
  • Table 113 Saudi Arabia liquid biopsy for early cancer detection and monitoring market, by Cancer, 2021 - 2033 (USD Million)
  • Table 114 Saudi Arabia liquid biopsy for early cancer detection and monitoring market, by Biomarker, 2021 - 2033 (USD Million)
  • Table 115 Saudi Arabia liquid biopsy for early cancer detection and monitoring market, by Technology, 2021 - 2033 (USD Million)
  • Table 116 Saudi Arabia liquid biopsy for early cancer detection and monitoring market, by End Use, 2021 - 2033 (USD Million)
  • Table 117 UAE liquid biopsy for early cancer detection and monitoring market, by Cancer, 2021 - 2033 (USD Million)
  • Table 118 UAE liquid biopsy for early cancer detection and monitoring market, by Biomarker, 2021 - 2033 (USD Million)
  • Table 119 UAE liquid biopsy for early cancer detection and monitoring market, by Technology, 2021 - 2033 (USD Million)
  • Table 120 UAE liquid biopsy for early cancer detection and monitoring market, by End Use, 2021 - 2033 (USD Million)
  • Table 121 Kuwait liquid biopsy for early cancer detection and monitoring market, by Cancer, 2021 - 2033 (USD)
  • Table 122 Kuwait liquid biopsy for early cancer detection and monitoring market, by Biomarker, 2021 - 2033 (USD Million)
  • Table 123 Kuwait liquid biopsy for early cancer detection and monitoring market, by Technology, 2021 - 2033 (USD Million)
  • Table 124 Kuwait liquid biopsy for early cancer detection and monitoring market, by End Use, 32021 - 2033 (USD Million)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Information procurement
  • Fig. 3 Market summary
  • Fig. 4 Market segmentation & scope
  • Fig. 5 Market size and growth prospects
  • Fig. 6 Global liquid biopsy for early cancer detection and monitoring market- Key market driver analysis
  • Fig. 7 Global liquid biopsy for early cancer detection and monitoring market- Key market restraint analysis
  • Fig. 8 Penetration & growth prospect mapping
  • Fig. 9 Global liquid biopsy for early cancer detection and monitoring market- Porter's analysis
  • Fig. 10 Global liquid biopsy for early cancer detection and monitoring market- PESTEL analysis
  • Fig. 11 Global liquid biopsy for early cancer detection and monitoring marketbiomarker outlook key takeaways
  • Fig. 12 Global liquid biopsy for early cancer detection and monitoring market: biomarker movement analysis
  • Fig. 13 Circulating Tumor DNA (ctDNA) market estimates, 2021 - 2033 (USD Million)
  • Fig. 14 Circulating Tumor Cells (CTCs) market estimates, 2021 - 2033 (USD Million)
  • Fig. 15 Exosomes/Microvesicles market estimates, 2021 - 2033 (USD Million)
  • Fig. 16 Circulating Proteins market estimates, 2021 - 2033 (USD Million)
  • Fig. 17 Global liquid biopsy for early cancer detection and monitoring markettechnology outlook key takeaways
  • Fig. 18 Global liquid biopsy for early cancer detection and monitoring market: technology movement analysis
  • Fig. 19 NGS (Next-Generation Sequencing) market estimates, 2021 - 2033 (USD Million)
  • Fig. 20 PCR-based assays (Digital PCR, RT-PCR) market estimates, 2021 - 2033 (USD Million)
  • Fig. 21 Microarray market estimates, 2021 - 2033 (USD Million)
  • Fig. 22 Epigenomics / Methylation assays market estimates, 2021 - 2033 (USD Million)
  • Fig. 23 Others market estimates, 2021 - 2033 (USD Million)
  • Fig. 24 Global liquid biopsy for early cancer detection and monitoring marketcancer outlook key takeaways
  • Fig. 25 Global liquid biopsy for early cancer detection and monitoring market: cancer movement analysis
  • Fig. 26 Lung cancer market estimates, 2021 - 2033 (USD Million)
  • Fig. 27 Breast cancer market estimates, 2021 - 2033 (USD Million)
  • Fig. 28 Colorectal cancer market estimates, 2021 - 2033 (USD Million)
  • Fig. 29 Prostate cancer market estimates, 2021 - 2033 (USD Million)
  • Fig. 30 Others market estimates, 2021 - 2033 (USD Million)
  • Fig. 31 Global liquid biopsy for early cancer detection and monitoring marketend use outlook key takeaways
  • Fig. 32 Global liquid biopsy for early cancer detection and monitoring market: end use movement analysis
  • Fig. 33 Hospitals market estimates, 2021 - 2033 (USD Million)
  • Fig. 34 Diagnostic Laboratories market estimates, 2021 - 2033 (USD Million)
  • Fig. 35 Others market estimates, 2021 - 2033 (USD Million)
  • Fig. 36 Regional marketplace: Key takeaways
  • Fig. 37 Global liquid biopsy for early cancer detection and monitoring market: Regional movement analysis
  • Fig. 38 North America liquid biopsy for early cancer detection and monitoring market, 2021 - 2033 (USD Million)
  • Fig. 39 U.S. liquid biopsy for early cancer detection and monitoring market, 2021 - 2033 (USD Million)
  • Fig. 40 Canada liquid biopsy for early cancer detection and monitoring market, 2021 - 2033 (USD Million)
  • Fig. 41 Mexico liquid biopsy for early cancer detection and monitoring market, 2021 - 2033 (USD Million)
  • Fig. 42 Europe liquid biopsy for early cancer detection and monitoring market, 2021 - 2033 (USD Million)
  • Fig. 43 UK liquid biopsy for early cancer detection and monitoring market, 2021 - 2033 (USD Million)
  • Fig. 44 Germany liquid biopsy for early cancer detection and monitoring market, 2021 - 2033 (USD Million)
  • Fig. 45 France liquid biopsy for early cancer detection and monitoring market, 2021 - 2033 (USD Million)
  • Fig. 46 Spain liquid biopsy for early cancer detection and monitoring market, 2021 - 2033 (USD Million)
  • Fig. 47 Italy liquid biopsy for early cancer detection and monitoring market, 2021 - 2033 (USD Million)
  • Fig. 48 Denmark liquid biopsy for early cancer detection and monitoring market, 2021 - 2033 (USD Million)
  • Fig. 49 Sweden liquid biopsy for early cancer detection and monitoring market, 2021 - 2033 (USD Million)
  • Fig. 50 Norway liquid biopsy for early cancer detection and monitoring market, 2021 - 2033 (USD Million)
  • Fig. 51 Asia Pacific liquid biopsy for early cancer detection and monitoring market, 2021 - 2033 (USD Million)
  • Fig. 52 Japan liquid biopsy for early cancer detection and monitoring market, 2021 - 2033 (USD Million)
  • Fig. 53 China liquid biopsy for early cancer detection and monitoring market, 2021 - 2033 (USD Million)
  • Fig. 54 India liquid biopsy for early cancer detection and monitoring market, 2021 - 2033 (USD Million)
  • Fig. 55 South Korea liquid biopsy for early cancer detection and monitoring market, 2021 - 2033 (USD Million)
  • Fig. 56 Australia liquid biopsy for early cancer detection and monitoring market, 2021 - 2033 (USD Million)
  • Fig. 57 Thailand liquid biopsy for early cancer detection and monitoring market, 2021 - 2033 (USD Million)
  • Fig. 58 Latin America liquid biopsy for early cancer detection and monitoring market, 2021 - 2033 (USD Million)
  • Fig. 59 Brazil liquid biopsy for early cancer detection and monitoring market, 2021 - 2033 (USD Million)
  • Fig. 60 Argentina liquid biopsy for early cancer detection and monitoring market, 2021 - 2033 (USD Million)
  • Fig. 61 MEA liquid biopsy for early cancer detection and monitoring market, 2021 - 2033 (USD Million)
  • Fig. 62 South Africa liquid biopsy for early cancer detection and monitoring market, 2021 - 2033 (USD Million)
  • Fig. 63 Saudi Arabia liquid biopsy for early cancer detection and monitoring market, 2021 - 2033 (USD Million)
  • Fig. 64 UAE liquid biopsy for early cancer detection and monitoring market, 2021 - 2033 (USD Million)
  • Fig. 65 Kuwait liquid biopsy for early cancer detection and monitoring market, 2021 - 2033 (USD Million)
  • Fig. 66 Strategy framework